Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer

Clinical Implications of Hedgehog Pathway Signaling in Prostate Cancer

(2015) Daniel Suzman et al.   Cancers

TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling

(2013) Naokazu Ibuki et al.   INTERNATIONAL JOURNAL OF CANCER

Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer

(2013) E. S. Antonarakis et al.   ONCOLOGIST

NVP-LDE-225 (Erismodegib) inhibits epithelial–mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128

(2013) R Nanta et al.   Oncogenesis

Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers

(2012) Eleni Efstathiou et al.   PROSTATE

Androgenic regulation of hedgehog signaling pathway components in prostate cancer cells

(2011) Mengqian Chen et al.   CELL CYCLE

Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth

(2010) James Kim et al.   CANCER CELL

Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling

(2008) Greg Shaw et al.   Cancer Cell International

Hedgehog Signalling in Androgen Independent Prostate Cancer

(2008) Greg Shaw et al.   EUROPEAN UROLOGY

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY